Clinical Cancer Research Abstracts
Careers
Contact | Tell Us About Your Study
Oncology Expertise
Immunotherapy
Operational Expertise
Investigator Relationships
Site Training
Indications
Services
Oncology CRO Services
Study Design
Study Launch
Study Management
Medical Writing
B/DM
Study Rescue
Drug Development Consulting
Access to the U.S. Market
Bioequivalence Design
Experience
Trial Experience
Drug Therapies
Rescue Studies
About
Approach
History
Leadership
Partners
Therapeutic Areas
Oncology
Dental
Nephrology
Medical Device and Diagnostics
Neurology and CNS
News/Blog
Home
Oncology Expertise
Services
Experience
About
Therapeutic Areas
News/Blog
Abstracts
Careers
Contact
Phase I
News
Thought leaders
Phase I
Contract research
Drug development
Phase I
How to Avoid Missing Patient Enrollment Targets in Your First Oncology Study
It’s common for sponsors to miss their patient…
Read Article
Phase I
Speed to market
Tips for Bringing Your First Oncology Drug into the Clinic in the United States
While cancer is a global health challenge, the…
Read Article
Drug development
Immunotherapy
Phase I
Preparing for Your Phase I Oncology Study
The phase 1 study is the gateway between…
Read Article
Phase I
Case Study: Rapid Phase I Study Start-Up and Conduct
A European client contracted with Medelis to conduct…
Read Article
Adaptive Trials
Phase I
Phase II
Thought leaders
Adaptive Trial Design for Phase I, Phase II
Adaptive trial design is a hot issue in…
Read Article
News
Phase I
Thought leaders
Medelis co-founder Daniel Von Hoff receives prestigious ASCO scientific honor
We are pleased to share the news that…
Read Article
Drug development
Phase I
Phase II
Speed to market
Thought leaders
“Context of vulnerability” and its role in targeted drug development
Renowned cancer researcher Dr. Daniel Von Hoff and…
Read Article
Contract research
Drug development
Phase I
Thought leaders
The “Lost Opportunity” in Phase I Oncology Trials
Cancer drug developers traditionally use the phase I…
Read Article
Contract research
Phase I
Preclinical studies
Speed to market
Insight: Preventing a Preclinical Dead End
Oncology preclinical studies are commonly viewed as straightforward…
Read Article
1
2
»
Last »